Abstract
4141 Background: The transarterial DEB-TACE) is a new treatment modality for hepatocellular carcinoma (HCC), whose effectiveness is poorly known. Aim: We prospectively studied the response rates to treatment and survival of patients with either Barcelona Clinic Liver Cancer (BCLC) A listed for liver transplantation (LT) or not suitable for radical therapy, and those with intermediate stage (BCLC B). Methods: 56 patients, mean age 64 yr, 36 Child-Pugh A, 24 Child-Pugh B, 32 BCLC A, 24 BCLC B, HCV related cirrhosis in 36 (64%), HBV in 1 (2%), ethanol in 7 (12%), mixed etiology in 10 (18%), cryptogenetic in 2 (4%). Serum alfafetoprotein (AFP) > 100 ng/mL in 17 (31%). Excluded were 2 patients with hypovascular tumors. DEB-TACE was repeated every other month with epirubicin (Pharmorubicin, Pfizer, Italy) loaded 100-300 μ m DC Bead (Biocompatibles, UK), until disappearance of tumor vascularization or disease progression by contrast CT scan, performed one month apart each treatment. Treatment response was evalua...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
